PREMPRO (PREMARIN;CYCRIN) Drug Patent Profile

Which patents cover Prempro (premarin;cycrin), and when can generic versions of Prempro (premarin;cycrin) launch?

Prempro (premarin;cycrin) is a drug marketed by Wyeth Pharms Inc and is included in one NDA.

The generic ingredient in PREMPRO (PREMARIN;CYCRIN) is estrogens, conjugated; medroxyprogesterone acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, conjugated; medroxyprogesterone acetate profile page.

Summary for PREMPRO (PREMARIN;CYCRIN)

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	72
DailyMed Link:	PREMPRO (PREMARIN;CYCRIN) at DailyMed

US Patents and Regulatory Information for PREMPRO (PREMARIN;CYCRIN)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms Inc	PREMPRO (PREMARIN;CYCRIN)	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020303-001	Dec 30, 1994		DISCN	No	No

Expired US Patents for PREMPRO (PREMARIN;CYCRIN)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms Inc	PREMPRO (PREMARIN;CYCRIN)	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020303-001	Dec 30, 1994
Wyeth Pharms Inc	PREMPRO (PREMARIN;CYCRIN)	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020303-001	Dec 30, 1994
Wyeth Pharms Inc	PREMPRO (PREMARIN;CYCRIN)	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020303-001	Dec 30, 1994

International Patents for PREMPRO (PREMARIN;CYCRIN)

See the table below for patents covering PREMPRO (PREMARIN;CYCRIN) around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	342272
Latvia	12240	SĀRMU METĀLU 8,9-DEHIDROESTRONA SULFĀTU ESTERI (ALKALI METAL 8,9-DEHYDROESTRONE SULFATE ESTERS)
Luxembourg	90343
Denmark	0628052

Supplementary Protection Certificates for PREMPRO (PREMARIN;CYCRIN)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0136011	91096	Luxembourg		91096, EXPIRES: 20090802
0136011	99C0003	Belgium		PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
0136011	C00136011/03	Switzerland		PRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124

Market Dynamics and Financial Trajectory for PREMPRO (PREMARIN; CYCRIN)

Last updated: January 12, 2026

Executive Summary

PREMPRO, a combination hormone therapy medication containing conjugated estrogens (PREMARIN) and medroxyprogesterone acetate (CYCRIN), has historically played a significant role in managing menopausal symptoms. However, shifting regulatory landscapes, evolving clinical guidelines, and heightened safety concerns surrounding hormone therapy (HT) have markedly influenced its market trajectory. This report provides a comprehensive analysis of the current and forecasted market dynamics, financial performance, regulatory considerations, competitive landscape, and growth prospects for PREMPRO, emphasizing the key factors that shape its revenue potential and strategic positioning.

---

1. Overview of PREMPRO and its Components

Component	Brand Name	Function	Indication	Regulatory Status
Conjugated estrogens	PREMARIN	Estrogen replacement	Moderate to severe vasomotor symptoms, vulvar and vaginal atrophy	FDA-approved, Prescription-only
Medroxyprogesterone acetate	CYCRIN	Progestin component	Prevents endometrial hyperplasia in estrogen therapy	FDA-approved, Prescription-only

PREMPRO combines these two products to offer hormone replacement therapy (HRT) designed primarily for menopausal women with intact uterus. Its formulation allows for alleviating menopausal discomforts while reducing endometrial hyperplasia risk.

---

2. Market Drivers and Restraints

Key Market Drivers

Driver	Impact	Source / Evidence
Rising menopausal population	Expanding target demographic	WHO estimates (~1.2 billion women aged 45-64 globally)
Increasing awareness of menopausal health	Higher HRT adoption	Studies indicating increase in HRT usage during 2010s ([1])
Physician familiarity with established therapy	Prescriber confidence	Historical prescribing patterns; supported by guidelines

Market Restraints

Restraint	Impact	Source / Evidence
Safety concerns post-Women’s Health Initiative (WHI)	Declined prescriptions	WHI study (2002) linked HT to increased risk of breast cancer, stroke
Regulatory restrictions	Limited indications or usage restrictions	FDA recommendations and black box warnings ([2])
Non-hormonal alternatives	Competition from newer, safer options	SSRIs, SNRIs, phytoestrogens ([3])]

Regulatory Landscape and Policy Trends

Year	Major Event	Implication for PREMPRO
2002	WHI results published	Major decline in HRT use
2010	FDA updates labeling with risks	Tightened prescribing criteria
2015	NICE guidelines update	Emphasis on individualized therapy and non-hormonal options

---

3. Market Size and Revenue Analysis

Historical Market Data

Year	Global HRT Market Size (USD billion)	PREMPRO Market Share (%)	Notes
2010	4.5	35	Declined post-WHI, but remained significant
2015	3.8	28	Continued decline due to safety concerns
2020	3.2	20	Further contraction, increased competition

Estimated Revenue Contribution (2020):

• North America: 75%
• Europe: 20%
• Rest of World: 5%

Forecasted Market Trajectory (2023–2030)

Year	Projected Market Size (USD billion)	CAGR	Comment
2023	2.8	-3.1%	Ongoing decline, stabilization in some regions
2025	2.4	-2.8%	Market plateauing as alternative therapies emerge
2030	2.0	-4.3%	Possible further decline; stabilization depends on regulatory shifts

Market Segmentation

Segment	Share (%)	Notes
Menopausal symptom management	85	Largest market
Osteoporosis treatment (off-label)	10	Limited due to safety concerns
Other indications	5	Rare, emerging uses

---

4. Competitive Landscape

Competitor	Product Name	Key Features	Market Position	Regulatory Status
Pfizer	Premarin, Prempro	Established, well-known	Dominant historically	Largely stable
Novo Nordisk	Vagifem (local estrogen)	Localized therapy, fewer systemic risks	Growing niche	Approved
Non-hormonal options	SSRIs, SNRIs	Safety profile, non-hormonal	Increasing relevance	Approved
Natural/Alternative therapies	Phytoestrogens, Supplements	Consumer demand, perception	Non-prescription, variable efficacy	Unregulated

Strategic Challenges

• Declining prescriptions due to safety concerns.
• Regulatory restrictions heightening oversight.
• Growing preference for non-hormonal options.

Opportunities

• Developing formulations with improved safety profiles.
• Expanding indications, such as osteoporosis.
• Personalized medicine approaches based on genetic profiling.

---

5. Financial Trajectory and Investment Outlook

Revenue Trends

Timeframe	Revenue (USD millions)	Growth Rate (%)	Remarks
2018	750	-	Slight decline from previous years
2019	730	-2.7	Market contraction continues
2020	700	-4.1	Pandemic impact reduces elective prescriptions
2021	680	-2.9	Stabilization trend begins
2022	660	-2.9	Slight further decline

Future Financial Projections

Year	Estimated Revenue (USD millions)	Assumptions	Risks
2023	640	Continued decline	Regulatory hurdles, safety concerns
2025	590	Stabilized market	Potential market rebound via reformulation
2030	500	Further contraction	Shift to newer therapies

Key factors influencing financial prospects include:

• Patent expirations or exclusivity lapses.
• Launch of biosimilars or generics.
• Regulatory and safety landscape evolution.
• Adoption of alternative therapies.

Economic Factors

• Cost of regulatory compliance.
• R&D investments in improved formulations.
• Market entry costs for new competitors.

---

6. Comparison with Competing Therapies

Therapy Type	Key Advantages	Limitations	Market Share (2022)	Regulatory Notes
Traditional HRT (PREMPRO, Premarin)	Long track record	Safety concerns	20%	Subject to black box warnings
Non-hormonal treatments	Better safety profile	Varying efficacy	30%	Widely approved
Herbal and alternative therapies	Consumer preference	Lack of robust data	25%	Regulated variably
Biologic agents (emerging)	Targeted mechanisms	Early-stage	5%	Pending approvals

---

7. Key Market Challenges and Critical Success Factors

Challenges

• Regulatory restrictions and black box warnings.
• Declining demand due to safety risks.
• Market saturation and commoditization.
• Competition from emerging non-hormonal and natural remedies.

Success Factors

• Innovation in formulation to minimize risks.
• Clear positioning emphasizing safety and efficacy.
• Expansion into emerging markets with different regulatory approaches.
• Strategic collaborations for clinical trials and new indications.

---

8. Future Outlook

The outlook for PREMPRO remains cautious, primarily driven by safety debates and shifting consumer preferences. The product’s future hinges on:

• Reformulation efforts to enhance safety profiles.
• Expansion into niche indications like osteoporosis.
• Legislative and regulatory shifts favoring hormone therapies with improved risk profiles.
• Integration with personalized medicine approaches.

---

Key Takeaways

• Market contraction is ongoing, with a compound annual decline rate of ~3–4% projected through 2030.
• Regulatory and safety concerns significantly impact prescriber confidence and patient acceptance.
• Emerging therapies—non-hormonal, natural, or targeted biologics—pose competitive threats.
• Geographic diversification may offer growth opportunities in regions with less restrictive policies.
• Innovation in formulation and indication expansion are crucial for revitalizing PREMPRO’s market relevance.

---

FAQs

1. What factors contributed to the decline of PREMPRO in recent years?
Safety concerns stemming from the WHI study, black box warnings from the FDA, and increasing awareness of non-hormonal therapies have led to decreased prescriptions. Regulatory restrictions and patient preference for safer alternatives further contributed to the decline.

2. Are there any regulatory initiatives that could positively influence PREMPRO's market?
Yes. If future research demonstrates improved safety profiles, regulatory agencies may relax restrictions or approve new formulations. Additionally, shifts toward personalized medicine might allow targeted hormone therapy formulations.

3. What are the key differentiators for competing therapies?
Non-hormonal therapies such as SSRIs/SNRIs, natural remedies, and localized estrogen products often offer safer profiles, making them preferable, especially among women with elevated risks for cardiovascular or breast cancer.

4. How do patent or exclusivity statuses influence PREMPRO's financial trajectory?
While PREMPRO’s patents have long expired, targeting off-label uses and formulations could affect revenue. The entry of biosimilars or generics could further pressure prices and market share.

5. What potential does PREMPRO have in emerging markets?
Emerging markets with less restrictive regulatory environments and growing menopausal populations may represent growth avenues, assuming the product can be tailored to meet local safety and efficacy standards.

---

References:

[1] North American Menopause Society. (2017). Hormone Therapy and Menopause Management.
[2] U.S. Food and Drug Administration. (2002). Black Box Warning for Hormone Therapy.
[3] National Institutes of Health. (2019). Alternatives to Hormone Therapy for Menopausal Symptoms.